by • April 13, 2016 • No Comments
The new breakthrough in harvesting pig organs for mammalian heart transplants has put the spotlight back on the efforts of most researchers around the world to assist solve the world’s organ shortage crisis. But there are other technologies being pursued that are seeking to assist alleviate this shortage — a few additional cutting edge than others.
That’s where bioprinting comes in. Bioprinting appears to use the talent of 3D printing devices to turn it into structures and objects of all kinds of shapes and sizes and turn those devices towards organic materials. And by organic, I mean organic. We’re talking of human tissues and organs that may assist replace the require for transplants by enabling patients in require to only obtain a 3D printed organ to replace a faulty one or assist speed up the healing system of injuries.
At the RoboUniverse 2013 conference in New York City on Tuesday, a startup called CELLINK created the case for bioprinting as the next of organs and tissue transplant, as well as drug research.
A spokesman for the company told attendees to imagine a next where organ shortages were no longer a problem; where no animals were at any time harmed in the testing of drugs and cosmetics.
CELLINK calls itself “the initially bioink company in the world.” The company is staking its position in bioprinting by saying it can donate not only the printing device requireed to turn it into various kinds of tissues — “Anything of skin, to cancer tumors [for studying drug effects], to liver parts” — but in addition provides the biomaterial requireed to turn it into a structure out of living cells.
Most importantly, CELLINK says the biological structures it can print through its bioink are created of cells that survive. In the world of synthetic biology, that’s an incredibly complex feat to complete outside of a living host. The ramifications may be extraordinarily massive.
But, CELLINK does not precisely have a proof of concept. The company has conducted studies to demonstrate the vitalent and efficacy of its bioink, but its yet a tough sell, as evidenced by CELLINK’s presentation at the conference. The company was vying for a $15,000 initially place prize in the Frontiertech Startup Showdown competition, and lost out to Dog Parker, that was able-bodied to manufacture a advantageous case on a working business version.
But, it may be wrong to write-off CELLINK and the bioprinting field as too far out. As researchers — both academic and of private companies — appear to manufacture new makes it to in biomedical applications and research, bioprinting stands a accident to quite become a valuable-bodied tool. CELLINK’s bioink may be seen by next generations as a forerunner for what medicine some day evolves into.
by admin • March 5, 2017
by admin • November 28, 2016
by admin • November 28, 2016